Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6190132 | Bulletin du Cancer | 2015 | 8 Pages |
Abstract
Monitoring and prevention of cardiovascular complications of anti-neoplastic treatment are currently well known for anthracyclines and trastuzumab but remain poorly implemented. The management of cardiac and vascular side effects of targeted therapies is not codified. The purpose of the platform heart-vessel cancer is to optimize the management of such complications within a small area (Vaucluse region of Arles). The platform will offer prescribers an easily accessible database, doctors performing exams standardized monitoring forms and patients a uniform follow-up. We report here the methodology of the elaboration of recommendations for clinical practice and the ways to develop the platform. After a year of active process, an analysis of the will be performed to see opportunities for improvement and dissemination on a larger scale.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Philippe Debourdeau, Catherine Meuleman, Ghislaine Dufaitre, Jean-Pierre Laroche, Borhane Slama, Safia Chebrek, Falah Aboukhoudir, Alice Mège, Robert Dotigny, Daniel Serin,